Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 20, 2021 08:00 ET | Source: FibroGen, Inc.

FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program

Exclusive license to anti-CCR8 monoclonal antibody program further strengthens FibroGen’s preclinical development pipelineHiFiBiO to receive $35 million option exercise payment, potential milestones...